The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Open accessAbstract
BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lenalidomide is the standard of care for maintenance therapy for most patients.142–147”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [142]
Experimental — accuracy not yet measuredIn the citing paper
“Patients who have disease progression while not on treatment with lenalidomide can often be re-treated effectively with this agent37,38, sometimes multiple times, and typically in combination with proteasome inhibitors such as carfilzomib39 and ixazomib40 or with daratumumab41.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationA note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,000
First-line treatment of multiple myeloma in both transplant and non-transplant candidates
Oriol, A., Abril, L., & Ibarra, G. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213891 · Cited by 2
Hashiguchi, M., Okamura, T., Nomura, K., Nakamura, T., Kawaguchi, K., Koteda, S., Morishige, S., Oku, E., Takata, Y., Seki, R., et al. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.747 · Cited by 2
Biran, N., Rowley, S. D., Vesole, D. H., Zhang, S., Donato, M. L., Skarbnik, A. P. Z., Richter, J. R., Pecora, A. L., & Siegel, D. S. D. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0534-0 · Cited by 2
Gorin, N. C. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.03.025 · Cited by 3
Total Marrow Irradiation in Multiple Myeloma
Sahebi, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-38692-4_10 · Cited by 2
Wahab, A., Rafae, A., Faisal, M. S., Mushtaq, K., Ehsan, H., Khakwani, M., Ashraf, A., Rehan, T., Ahmed, Z., Shah, Z., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1839886 · Cited by 2
Kalff, A., Khong, T. T., Ramachandran, M., Walker, P., Schwarer, A. P., Roberts, A. W., Campbell, P. J., Filshie, R., Norton, S., Reynolds, J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1948030 · Cited by 2
Lenalidomide maintenance in myeloma
Gozzetti, A., Defina, M., & Bocchia, M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100-c1 · Cited by 2
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Leukemia · doi:10.1038/s41375-018-0359-7 · Cited by 2
Dhanasiri, S. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0749-0 · Cited by 2
Shi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Développements thérapeutiques en hématologie au XXIe siècle
Gorin, N. C. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.07.005 · Cited by 1
Slade, M., Fiala, M. A., Kirchmeyer, M., King, J., Gao, F., Schroeder, M. A., Stewart, A. K., Stockerl-Goldstein, K. E., Chen, C. I., & Vij, R. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.014 · Cited by 1
Tanguay, M., Roy, J., Su, J., Gul, E., Reece, D. E., Venner, C. P., White, D. J., Chu, M. P., Jimenez‐Zepada, V. H., Song, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70332 · Cited by 1
Alhejazi, A., Alhuraiji, A., Nourallah, A., Alshehri, A. A., Usman, B., ElGohary, G. M., Malhan, H. M., Motabi, I., Farsi, K. A., Alshuaibi, M., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1547138 · Cited by 1
Secondary neoplasms following treatment for multiple myeloma
Germans, S. K., Zhang, B., & Weinberg, O. K. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150976 · Cited by 1
NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma
Hu, B., Edwards, J. T., Modi, H., Gamez, J., Echeagaray, O. E., Hess, K. N., Ren, Y., Anderson, D., Larráyoz, M., Zhu, J., et al. (2026) · Blood · doi:10.1182/blood.2025031998 · Cited by 1
Hagen, P. A., Norton, J. A., Tsai, S., Campo, L., Lee, M., Gomez, K. D., & Stiff, P. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19281 · Cited by 1
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar, F. Z., & Gorshein, E. (2025) · Advances in Hematology · doi:10.1155/ah/6622365 · Cited by 1
First-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 1
Nørgaard, J. N., Moore, K. L. F., Slørdahl, T. S., Vik, A., Tvedt, T. H. A., Monsen, H. B., & Schjesvold, F. H. (2026) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.25.0498 · Cited by 1
Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O. A., Mewawalla, P., Shah, M. R., Lutfi, F. U., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050249 · Cited by 1
Yohannan, B., Langworthy, B., Turner, L. E., Dispenzieri, A. A., Buadi, F. K., Dingli, D., Leung, N., Kapoor, P., Gonsalves, W. I., Kourelis, T., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01537-4 · Cited by 1
Multiple myeloma – current status and future directions
Rasche, L., & Knop, S. T. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.841577 · Cited by 1
Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Agents
Shimazaki, C. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.004 · Cited by 1
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
Fillitz, M., Seebacher, A., & Panny, M. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0206-8 · Cited by 1
Straka, C., Salwender, H. J., Schnabel, B., Sandherr, M., Wandt, H., Hübel, K., Scheid, C., Metzner, B., Hentrich, M., Franke, D., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.919631 · Cited by 1
Risk of Secondary Primary Malignancies in Maintenance Therapy for Multiple Myeloma
Schecter, J. M., & Lentzsch, S. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.38 · Cited by 1
A man with a fracture from minor trauma
Yang, S. M., & Lo, C. M. (2014) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.issn.1920-8642.2014.04.011 · Cited by 1
Autologous Stem Cell Transplantation In Multiple Myeloma: Is It Still The Right Choice?
Tosi, P. (2014) · EMJ Hematology · doi:10.33590/emjhematol/10311182 · Cited by 1
Autologous stem cell transplantation for multiple myeloma: history and future
Shimazaki, C. (2013) · Cited by 1
Yamamoto, M., Ohashi, K., Kakihana, K., Nakamura, Y., Komeno, T., Kojima, H., Morita, S., & Sakamaki, H. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.833 · Cited by 1
Malenda, A., Kołkowska‐Leśniak, A., Szumera‐Ciećkiewicz, A., Lech‐Marańda, E., & Warzocha, K. (2016) · Hematologia · doi:10.5603/hem.2016.0006 · Cited by 1
Treatment of t(4;14) and del(17p) in Multiple Myeloma
Sonneveld, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_4 · Cited by 1
Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma
Jagosky, M. H., Taneja, A., & Bhutani, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_2 · Cited by 1
How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy
Montefusco, V., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8954 · Cited by 1
Rath, C. G., Yoo, C., Cheplowitz, H., Lo, M., Young, R., Guglielmo, J., Saunders, I. M., Banerjee, R. K., Young, R. B., Kumar, A. D., et al. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221150935 · Cited by 1
Lenalidomide maintenance in Myeloma – a goldilocks problem?
Ng, M., & Khot, A. S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2255325 · Cited by 1
Advanced practice nurse management in multiple myeloma treated with oral therapy
Sapet, M., Migala, C., Daguenet, É., Collet, P., Boussoualim, K., Thomas, T., Guyotat, D., & Augeul-Meunier, K. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.07.010 · Cited by 1
Nielsen, L. K., Schjesvold, F. H., Möller, S., Guldbrandsen, N., Hansson, M., Remes, K., Pečeliūnas, V., Abildgaard, N., Gregersen, H., & King, M. T. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00691-2 · Cited by 1
Prevention and Treatment of Relapse by Drugs
Kröger, N. M., & Gagelmann, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-44080-9_58 · Cited by 1
Buck, C., Castillo, F. B., Bettio, E., Land, J., McCourt, O., Poole, H. M., Tarling, R., Yong, K., Popat, R., Lee, L. S. H., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08663-4 · Cited by 1
Zhong, Q., Meng, F., Chen, H.-Y., Li, X., Wang, X.-G., Huang, S., Wu, M.-Y., Yu, J., Xue, Y., Wu, Y.-H., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06219-y · Cited by 1
Aziz, N. I. A., Palaniappan, S., Rodin, N. S. K., Chong, G. Y., Jerome, T. T. C., Aizuddin, A. N., & Tumian, N. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030759 · Cited by 1
Li, Z., Zhang, W., Huang, F., & Hao, S. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100575 · Cited by 1
Landgren, O., Biran, N., O’Donnell, E., Mikhael, J. R., Weisel, K. C., Broijl, A., Usmani, S. Z., Moreau, P., Gay, F., Mina, R., et al. (2025) · HemaSphere · doi:10.1002/hem3.70178 · Cited by 1
Self-citationConsolidation and Maintenance in De Novo First-Line Multiple Myeloma with Modern Agents
Stoppa, A. M., Coso, D., Fouquet, G., & Leleu, X. P. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.3 · Cited by 1
Self-citationRabin, N. K., Lai, M., Pratt, G., Morgan, G. J., Snowden, J. A., Bird, J. M., Cook, G., Bowcock, S. J., Owen, R. G., Yong, K., et al. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12205 · Cited by 1
Ueda, T., Iino, R., Yokoyama, K., Okamoto, S., Asakura, K., Tsukada, Y., Ishizawa, J., Matsuki, E., Ikeda, Y., & Hattori, Y. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1166-y · Cited by 1
Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
Roziaková, Ĺ., & Mistrík, M. (2013) · Klinicka onkologie · doi:10.14735/amko2013186 · Cited by 1
Autologous stem cell transplantation for multiple myeloma
Nakamura, M., & Sunami, K. (2014) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct.3.64 · Cited by 1
Treatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 1
Prevention and Treatment of Relapse by Drugs
Kröger, N. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_58 · Cited by 1
Yao, W. Q., Zhu, M., Yan, L. Z., Jin, S., Shang, J. J., Yao, Y., Yan, S., Liu, Y., Wu, D. P., & Fu, C. C. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.09.002 · Cited by 1
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Kumar, L. (2020) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0040-1712792 · Cited by 1
Maintenance regimens after a second autologous transplant for multiple myeloma
Mohyuddin, G. R., Okoniewski, M., Diab, O. A., Ganguly, S., Shune, L. O., Abdallah, A.-O. A., McGuirk, J. P., & McClune, B. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1842402 · Cited by 1
Dong, X., Zhang, Z., Shou, L., & Shen, J. (2021) · Medicine · doi:10.1097/md.0000000000024647 · Cited by 1
Parmar, H. V., Saleh, A. S. A., Visram, A., Warsame, R. M., Kourelis, T., Gonsalves, W. I., Dingli, D., Muchtar, E., Hayman, S. R., Kapoor, P., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.11.022 · Cited by 1
Han, X., Jin, C., Zheng, G., He, D., Zhao, Y., Li, Y., Wu, W., Zheng, W., Wei, G., Zhang, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665217 · Cited by 1
The evolving role and utility of off-label drug use in multiple myeloma
Stoeckle, J. H., Davies, F. E., Williams, L. S., Boyle, E. M., & Morgan, G. J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00050 · Cited by 1
Multiple Myeloma: Risk Stratification and Toxicity Management
Richards, T., & Lee, H. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.3.10 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Maintenance therapy in multiple myeloma: Two is not always better than one
Offidani, M., Morè, S., & Corvatta, L. (2022) · British Journal of Haematology · doi:10.1111/bjh.18614 · Cited by 1
Jain, P. L., Jain, P., Tikoo, A., Singh, T., Patkar, S., Lokhande, V., Mishra, A., Agarwal, B., Haridas, A., & Khandelwal, K. (2024) · Apollo Medicine · doi:10.1177/09760016241239849 · Cited by 1
Issues of front-line therapy for multiple myeloma – the standard of care
Rosiñol, L., & Bladé, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.896460 · Cited by 1
Perry, C., & Polliack, A. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.881481 · Cited by 1
Transplantation for Myeloma: Work in Progress
Palumbo, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1437 · Cited by 1
Future needs and wants in medical education--the UPM experience.
Azhar, M. Z. (2005) · PubMed · Cited by 1
Galy, A. S. D., Michonneau, D., & Socié, G. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch12 · Cited by 1
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
Mian, H. S., & Costa, L. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2604761 · Cited by 1
Schuster, S. R., & Mikhael, J. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_23
Zielgerichtete Therapien bei hämatologischen Erkrankungen
Hochhaus, A., Rosée, P. G. L., Mügge, L., Sayer, H. G., & Scholl, S. (2013) · Der Onkologe · doi:10.1007/s00761-013-2497-x
Konsolidierungs- und Erhaltungstherapie beim multiplen Myelom
Zojer, N., & Ludwig, H. (2014) · Der Onkologe · doi:10.1007/s00761-013-2572-3
Allogeneic Hematopoetic Cell Transplantation in Multiple Myeloma
Topçuoğlu, P., Civriz, S., & Demirer, T. (2013) · InTech eBooks · doi:10.5772/54762 · Cited by 1
Cell cycle regulation and myeloma precursor cells
Quinn, J., & Yong, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.004
Treatment of transplant-eligible patients
Mohty, M., Malard, F., & Harousseau, J. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6_3
Self-citationAdvanced flow cytometry to study signaling pathways and predict outcome in B cell malignancies
Blix, E. S. (2015) · NORA - Norwegian Open Research Archives
Autologous Stem Cell Transplantation in the Management of Multiple Myeloma
Gertz, M. A., & Reeder, C. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_10
The Devil is in the Details: Confidentiality Challenges in the Age of Genetics
Daly, B. J., Rosko, A. E., Zhang, S., & Lazarus, H. M. (2014) · HEC Forum · doi:10.1007/s10730-014-9245-5
Impediments to Curing Myeloma in 2012
Chauhan, N., Barlogie, B., & Usmani, S. Z. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.11
Clinical Pathologic Conference Case 2: A Diffuse Swelling of the Neck
Ferreira, L., Efebera, Y. A., & Allen, C. M. (2013) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2013.01.045
Stellenwert der autologen Stammzelltransplantation und der Lenalidomid-Erhaltung
Rasche, L., & Einsele, H. (2015) · Info Onkologie · doi:10.1007/s15004-015-0760-6
What Can We Attribute Secondary Malignancy to: Drugs or the Innate System?
Johnson, S., Barlogie, B., & Usmani, S. Z. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.34
Lenalidomide maintenance in myeloma
Rajkumar, S. V. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100-c2
The evolving field of post-transplant therapy in multiple myeloma
Holstein, S. A., & McCarthy, P. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.72
Post-transplant therapy in multiple myeloma: a hung jury?
Kumar, S. K. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00024-6
POMALIDOMID – nowy immunomodulujący lek w terapii szpiczaka plazmocytowego
Jurczyszyn, A. J., Usnarska‐Zubkiewicz, L., Engel, A., Butrym, A. K., Mazur, G. J., & Skotnicki, A. B. (2014) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2014.04.003
Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma
Lonial, S. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.6
Leczenie podtrzymujące w szpiczaku plazmocytowym
Grosicki, S. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.02.012
Giebel, S., & Saduś‐Wojciechowska, M. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)34002-4
Evans, H. L. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000141
Maintenance Therapy for Multiple Myeloma After an Autologous Transplant: What Have We Learned?
Adekola, K., & Qazilbash, M. H. (2014) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.70
High-Risk Myeloma: When To Transplant—Or Not
Eicher, D. M., Lonial, S., Cavallo, F., Palumbo, A. P., Nair, B. P., Waheed, S., Hofmeister, C. C., & Rogers, H. J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.016
Deriving New Treatment Strategies in Multiple Myeloma
Podar, K. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.10
Multiple myeloma: optimal management and long-term disease control
Sriskandarajah, P., & Davies, F. E. (2014) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s46576
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Future Oncology · doi:10.2217/fon.15.51
Autologe Stammzelltransplantation bei Myelompatienten
Zojer, N. (2015) · Wiener klinisches Magazin · doi:10.1007/s00740-015-0077-y
Continuous therapy with lenalidomide in multiple myeloma
Bahlis, N. J. (2013)
Metadata
- Authors
- Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.-C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., & Harousseau, J.-L.
- Affiliations
- Hôpital Purpan (FR)
- CHU Dijon Bourgogne (FR)
- Hôpital Claude Huriez (FR)
- Institut Paoli-Calmettes (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hôpital Saint-Antoine (FR)
- Hôpital Pontchaillou (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Edouard Herriot (FR)
- Institut Curie (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-10
- Volume
- 366
- Issue
- 19
- Pages
- 1782-1791
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128084036
- Semantic Scholar
- c28c0ef900dcfd0347dbf26ecd97d5547f948a9a
- Cited by
- 1,155
- References
- 24
- Citations by year
- 2026: 32 · 2025: 36 · 2024: 43 · 2023: 61 · 2022: 70 · 2021: 85 · 2020: 79 · 2019: 68 · 2018: 83 · 2017: 98 · 2016: 108 · 2015: 86 · 2014: 102 · 2013: 133 · 2012: 68
- FWCI
- 82.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- lenalidomide, maintenance therapy, multiple myeloma, autologous stem cell transplantation, progression-free survival, event-free survival, secondary malignancies, peripheral neuropathy, young patients, residual disease
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
